VVUS - VIVUS, Inc.
| Previous Close | 0.36 |
| Open | 0.36 |
| Bid | 0.35 x 100 |
| Ask | 0.42 x 8100 |
| Day's Range | 0.36 - 0.38 |
| 52 Week Range | 0.33 - 1.38 |
| Volume | 179,374 |
| Avg. Volume | 620,254 |
| Market Cap | 38.168M |
| Beta | 0.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.29 |
| Earnings Date | May 1, 2018 - May 7, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.50 |
- Marketwired•3 hours ago
VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Tuesday, May 8, 2018
VIVUS, Inc. today announced that it will report financial results and provide a business update for the first quarter of 2018 after the market close on Tuesday, May 8, 2018. The company will host a conference ...
- Zacks•13 days ago
Why Is VIVUS (VVUS) Down 18% Since its Last Earnings Report?
VIVUS (VVUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Associated Press•last month
Vivus reports 4Q loss
On a per-share basis, the Campbell, California-based company said it had a loss of 10 cents. The biopharmaceutical company posted revenue of $11.9 million in the period. For the year, the company reported ...
- Marketwired•last month
VIVUS Reports Fourth Quarter 2017 Financial Results
VIVUS,Inc. , a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported ...
- ACCESSWIRE•2 months ago
Today’s Research Reports on Trending Tickers: Arena Pharmaceuticals and VIVUS
NEW YORK, NY / ACCESSWIRE / February 9, 2018 / U.S. markets continued to plunge alongside rising interest rates on Thursday. The Dow Jones Industrial Average dropped 4.15 percent to close at 23,860.46, ...
- Marketwired•4 months ago
VIVUS Announces Change in Leadership
VIVUS, Inc. today announced that it has reached agreement with Seth H. Z. Fischer pursuant to which he will step down as chief executive officer and a member of the board of directors effective December ...
- Capital Cube•5 months ago
ETFs with exposure to VIVUS, Inc. : November 20, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VIVUS, Inc. Here are 5 ETFs with the largest exposure to VVUS-US. Comparing the performance and risk of VIVUS, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of VVUS earnings conference call or presentation 7-Nov-17 9:30pm GMT
Q3 2017 VIVUS Inc Earnings Call
- Zacks•5 months ago
VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down
VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.
Capital Cube•5 months agoVIVUS, Inc. :VVUS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
Categories: Yahoo FinanceGet free summary analysis VIVUS, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of VIVUS, Inc. – Apricus Biosciences, Inc., Pfizer Inc., Cardinal Health, Inc., Eli Lilly and Company, AmerisourceBergen Corporation and Arena Pharmaceuticals, Inc. (APRI-US, PFE-US, CAH-US, LLY-US, ABC-US and ARNA-US) that ... Read more (Read more...)
- Associated Press•6 months ago
Vivus reports 3Q loss
The Campbell, California-based company said it had a loss of 6 cents per share. The biopharmaceutical company posted revenue of $15.2 million in the period. In the final minutes of trading on Tuesday, ...
- Marketwired•6 months ago
VIVUS Reports Third Quarter 2017 Financial Results
VIVUS, Inc. , a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported ...
- ACCESSWIRE•6 months ago
VIVUS, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 7, 2017 / VIVUS, Inc. (NASDAQ: VVUS ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 7, 2017 at 4:30 PM Eastern Time. To ...
- Marketwired•6 months ago
VIVUS Completes Tacrolimus Pre-IND Meeting With FDA
VIVUS, Inc. , a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced ...
- Marketwired•6 months ago
VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 7, 2017
VIVUS, Inc. today announced that it will report financial results and provide a business update for the third quarter of 2017 after the market close on Tuesday, November 7, 2017. The company will host ...
- Capital Cube•6 months ago
ETFs with exposure to VIVUS, Inc. : October 30, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VIVUS, Inc. Here are 5 ETFs with the largest exposure to VVUS-US. Comparing the performance and risk of VIVUS, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Capital Cube•7 months agoVIVUS, Inc. :VVUS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
Categories: Yahoo FinanceGet free summary analysis VIVUS, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 11.23 million, Net Earnings of USD -13.39 million. Gross margins narrowed from 80.79% to 68.20% compared to the same period last year, operating (EBITDA) margins now -42.20% from -24.58%. Change in operating cash ... Read more (Read more...)
- Zacks•7 months ago
Orexigen's (OREX) Contrave Sales Improving on Promotions
Despite competition, Orexigen Therapeutics' (OREX) obesity drug, Contrave has performed well so far this year driven by the company's promotional strategies.
- ACCESSWIRE•8 months ago
VIVUS, Aggressive Marketing For Approved Drugs, Milestone for Tacrolimus, Pipeline Analysis
NEW YORK, NY / ACCESSWIRE / September 8, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
- Zacks•8 months ago
VIVUS Gives Rights to Alvogen in Korea for Anti-Obesity Drug
VIVUS, Inc. (VVUS) signed an agreement with Alvogen giving rights to the latter to market anti-obesity drug Qsymia in Korea for the treatment of chronic weight management or weight-related conditions.
- Marketwired•8 months ago
VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension
VIVUS, Inc. , a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced ...
- Marketwired•8 months ago
VIVUS and Alvogen Announce Marketing Agreement for Qsymia(R) in the Republic of Korea
VIVUS, Inc. and Alvogen Malta Operations Ltd, today announced an agreement under which Alvogen will market Qsymia® in the Republic of Korea for the treatment of chronic weight...
- Zacks•8 months ago
VIVUS (VVUS) Down 19.8% Since Earnings Report: Can It Rebound?
VIVUS (VVUS) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
